Semaglutide Improves Heart Failure Functional Class, Especially in Sickest Patients

Semaglutide improved NYHA class in 32.6% vs 21.5% placebo (OR 2.20, P<0.001). Deterioration occurred in only 2.1% vs 5.2% (OR 0.36, P=0.003). KCCQ-CSS improvement was especially pronounced in NYHA III/IV (10.5 points vs 6.0 in class II). Weight loss was consistent (~8.4%) regardless of baseline NYHA class. Consistent improvements in 6MWD, CRP, and NT-proBNP across all categories.

Prespecified pooled analysis of STEP-HFpEF and STEP-HFpEF DM — two international, double-blind, placebo-controlled RCTs. 1,145 participants with obesity-related HFpEF randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks. Primary outcome: change in NYHA functional class. Secondary: KCCQ-CSS, 6MWD, bodyweight, CRP, NT-proBNP by baseline NYHA class.

NYHA functional class is one of the most important clinical measures in heart failure — it directly reflects how heart failure limits daily life. Showing that semaglutide improves functional status, with the biggest gains in the most limited patients, demonstrates meaningful clinical benefit beyond just weight loss.

This analysis strengthens the case for semaglutide as a true heart failure therapy — not just a weight loss drug that incidentally helps the heart. The finding that the sickest patients benefit most suggests semaglutide should be considered earlier and more aggressively in obese HFpEF, particularly for patients with significant functional limitations.

Post-hoc pooled analysis — though prespecified, it combines two trials with slightly different populations (with and without T2D). NYHA classification is somewhat subjective. 52-week follow-up may not capture durability of functional improvement. The sickest patients (NYHA IV) were underrepresented.